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Imported Dengue 
Hemorrhagic Fever, 
Europe
To the Editor: Dengue infection 
is an endemic and epidemic urban 
disease (1), transmitted by infected 
Aedes mosquitoes. Its incidence is 
increasing in tropical and subtropical 
areas (1,2) because of 1) introduction 
of the virus into areas where it was not 
previously endemic, and 2) the spread 
of the 4 serotypes and the vector in 
disease-endemic areas (2,3). Infec-
tion with 1 serotype provides lifelong 
homologous immunity only for that 
serotype, and after a few months, the 
presence of nonneutralizing antibod-
ies increases the risk for progression 
to dengue hemorrhagic fever (DHF) 
or dengue shock syndrome when the 
patient is infected by any of the other 3 
serotypes (3,4). We report an imported 
case with severe clinical manifesta-
tions that fulﬁ  lls DHF criteria (5).
A 33-year-old Spanish woman 
who had worked in Anantapur, In-
dia, for 180 days, returned to Spain 
on August 1, 2007; on August 3, she 
traveled to Dubrovnik, Croatia, on 
holiday. She also had visited Thailand 
45 days before August 1 and Brazil 2 
years ago. Two months previously, she 
experienced a 3-day episode of fever 
that spontaneously resolved but with-
out laboratory evidence of dengue. On 
August 6, she exhibited a high fever, 
chills, headache, arthralgia, and myal-
gia, with hypotension and was admit-
ted to the hospital. Three days later, a 
conﬂ   uent maculopapular rash devel-
oped. Dubrovnik hospital laboratory 
values were hemoglobin (Hb) 143 
g/L, packed cell volume (PCV) 41.6%, 
mean corpuscular volume (MCV) 
84.6 fL, platelet count 97 × 109/L, leu-
kocyte count 1.96 × 109/L, aspartate 
aminotransferase (AST) 45 U/L, ala-
nine aminotransferase (ALT) 31 U/L, 
AP 73 U/L, and lactate dehydrogenase 
(LDH) 198 U/L. On the ﬁ  fth day of 
illness, platelet count was 50 × 109/L. 
Because viral hemorrhagic fever was 
suspected, the patient was referred to 
a specialized hospital in Zagreb. Chest 
radiograph and abdominal ultrasound 
scan showed bilateral pleural and peri-
toneal effusions. 
The patient was treated with ﬂ  uid 
and plasma replacement, antipyretics, 
and ceftriaxone plus doxycycline to 
counteract bacterial and other possible 
tick-borne infections. She was placed 
under strict isolation measures while 
awaiting ﬁ  nal diagnosis. The patient 
was transferred to Barcelona (Spain) 
University Hospital on August 14; on 
the basis of her clinical symptoms, 
hemorragic fever was suspected. She 
exhibited headache, arthralgia, and 
myalgia. The fever subsided 9 days 
after the onset of symptoms. Clinical 
examination showed a maculopapular 
rash involving the face, thorax, limbs, 
and palms and soles, with diffuse pete-
chiae and bruising (Figure). Barcelona 
University Hospital laboratory values 
were Hb 105 g/L, PCV 32%, MCV 86, 
prothrombin time 12.4 s, AST 347 U/L, 
ALT 322 U/L, gamma-glutamyl trans-
ferase 114 U/L, alkaline phosphatase 
194 U/L, LDH 544 U/L, bilirubin 0.5 
mg/dL, and C-reactive protein level 
6.93 mg/dL. Platelet count and renal 
function were within normal limits. 
Urine, blood, and stool cultures were 
all negative for bacterial infections. 
Serologic tests on day 3 and day 
11 after the onset of symptoms were 
not reactive for Crimea-Congo hem-
orrhagic fever (CCHF), chikungunya, 
yellow fever, Hantaan, Puumala, and 
Dobrava viruses; HIV 1 and 2; parvo-
virus B19; cytomegalovirus; Epstein-
Barr virus; or rickettsial diseases. Im-
munoglobulin (Ig) M tests on day 3 
for all 4 dengue virus serotypes were 
negative. Positive IgG were 1:320 
(type 1) and 1:100 (type 3 and 4). A 
second sample on day 11 showed all 
4 IgG serotypes >1:10,000, and IgM 
>1:10,000 for serotypes 1, 2, and 4. 
Results of real-time PCR for CCHF 
were negative but reverse transcrip-
tion–PCR multiplex for dengue virus 
was positive for dengue type 1 virus. 
The patient recovered and was moni-
tored for 2 months.
Since 1977, 15 cases of imported 
DHF have been reported in Europe 
(6,7). The 4 World Health Organiza-
tion (WHO) criteria for DHF diagno-
sis are 1) fever related to the current 
process, 2) hemorrhagic manifesta-
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Figure. Maculopapular rash with diffuse petechiae, with areas of normal skin and bruising 
under the breast.LETTERS
tions, 3) low levels of platelets (<100 
× 109/L) and 4) increased capillary 
permeability (5). Our patient fulﬁ  lled 
all 4 criteria. Few cases of reported 
DHF fulﬁ  ll criterion 3 due to the short 
duration of severe thrombocytopenia 
in mild clinical forms (8). Increased 
vascular permeability was shown in 
our patient by the peritoneal and bilat-
eral pleural effusions.
The probability of diagnosing 
dengue fever in Europe increases with 
travel to dengue-endemic areas, in 
view of the increase of DHF numbers 
(2006–2007) and several outbreaks 
around the world, even during the non-
dengue season (9). Frequent travelers 
are more at risk for DHF. In a recent 
European publication, 17% of patients 
with imported dengue fever exhibited 
a secondary immune response, thus 
having a higher risk of developing 
DHF in the future (6). Serologic tests 
conﬁ   rm dengue infection only if a 
4-fold increase in titers in consecutive 
serum samples occurs, as in our case.
In dengue-endemic areas, despite 
the higher disease incidence, many 
cases still fail to meet WHO criteria 
(9). A comprehensive revision of den-
gue and DHF series (8) shows differ-
ences in applying WHO criteria for di-
agnosis, and sometimes the correlation 
was poor between criteria-fulﬁ  lling 
cases and severity of disease. Some 
reports (6,8) suggest that WHO cri-
teria should be reviewed and perhaps 
new parameters should be established 
to deﬁ  ne severe dengue disease.
Although our patient was not in-
fected in Europe, lessons from the 
recently described chikungunya out-
break in Italy indicate the possibility of 
new arbovirus outbreaks in previously 
non–disease-endemic areas due to the 
increasingly established presence of 
vectors like Ae. albopictus (10).
Dengue virus infection should 
therefore be considered in the differ-
ential diagnosis of fever in returning 
travelers. DHF diagnosis, although 
unusual, could become more frequent 
in the future.
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Mycobacterium 
setense Infection in 
Humans
To the Editor: A 66-year-old man 
had a bone graft for treatment of an 
oroantral ﬁ  stula in March 2007 in Mar-
seille, France. The surgery consisted of 
a bilateral maxillary sinus ﬁ  lling with 
a parietal osseous graft to close the ﬁ  s-
tula (position 24–25). Painful edema of 
the hemiface and mild fever developed 
in the patient in July 2007. Computed 
tomography showed areas of hypoden-
sity in the osseous graft in the left max-
illary sinus consistent with osteolysis. 
Microscopic examination of a bone 
biopsy specimen after gram staining 
did not reveal any organisms but this 
specimen did grow Enterobacter cloa-
cae  and colonies of a gram-positive 
bacillus after a 2-day inoculation on 
5% blood agar incubated at 37°C in 
an atmosphere of 5% CO2. Tentative 
identiﬁ  cation of this catalase-positive, 
oxidase-negative gram-positive rod 
(isolate 74023791) by an API Coryne 
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